ES3032492T3 - Hspc-sparing treatments for rb-positive abnormal cellular proliferation - Google Patents

Hspc-sparing treatments for rb-positive abnormal cellular proliferation

Info

Publication number
ES3032492T3
ES3032492T3 ES14765105T ES14765105T ES3032492T3 ES 3032492 T3 ES3032492 T3 ES 3032492T3 ES 14765105 T ES14765105 T ES 14765105T ES 14765105 T ES14765105 T ES 14765105T ES 3032492 T3 ES3032492 T3 ES 3032492T3
Authority
ES
Spain
Prior art keywords
compound
positive
cancer
cells
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14765105T
Other languages
English (en)
Spanish (es)
Inventor
Jay Strum
John Bisi
Patrick Roberts
Francis Tavares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
Pharmacosmos Holding AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3032492(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding AS filed Critical Pharmacosmos Holding AS
Application granted granted Critical
Publication of ES3032492T3 publication Critical patent/ES3032492T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
ES14765105T 2013-03-15 2014-03-14 Hspc-sparing treatments for rb-positive abnormal cellular proliferation Active ES3032492T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361798772P 2013-03-15 2013-03-15
US201361861374P 2013-08-01 2013-08-01
US201361911354P 2013-12-03 2013-12-03
US201461949786P 2014-03-07 2014-03-07
PCT/US2014/029429 WO2014144847A2 (en) 2013-03-15 2014-03-14 Hspc-sparing treatments for rb-positive abnormal cellular proliferation

Publications (1)

Publication Number Publication Date
ES3032492T3 true ES3032492T3 (en) 2025-07-21

Family

ID=51527871

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14762438T Active ES2761406T3 (es) 2013-03-15 2014-03-14 Protección transitoria de células normales durante una quimioterapia
ES14765105T Active ES3032492T3 (en) 2013-03-15 2014-03-14 Hspc-sparing treatments for rb-positive abnormal cellular proliferation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14762438T Active ES2761406T3 (es) 2013-03-15 2014-03-14 Protección transitoria de células normales durante una quimioterapia

Country Status (18)

Country Link
US (15) US9464092B2 (enExample)
EP (4) EP4596051A3 (enExample)
JP (9) JP6430483B2 (enExample)
CN (4) CN105407889B (enExample)
CA (2) CA2906156C (enExample)
CY (1) CY1122434T1 (enExample)
DK (1) DK2968290T3 (enExample)
ES (2) ES2761406T3 (enExample)
HR (1) HRP20192168T1 (enExample)
HU (1) HUE046653T2 (enExample)
LT (1) LT2968290T (enExample)
ME (1) ME03557B (enExample)
PL (1) PL2968290T3 (enExample)
PT (1) PT2968290T (enExample)
RS (1) RS59790B1 (enExample)
SI (1) SI2968290T1 (enExample)
SM (1) SMT201900681T1 (enExample)
WO (2) WO2014144847A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
US9464092B2 (en) * 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
ES2924371T3 (es) 2015-06-17 2022-10-06 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CN108348514A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
JP6635374B2 (ja) * 2015-12-18 2020-01-22 京都府公立大学法人 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法
WO2017161253A1 (en) * 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
ES2908801T3 (es) 2016-06-07 2022-05-04 Jacobio Pharmaceuticals Co Ltd Nuevos derivados heterocíclicos útiles como inhibidores de SHP2
NZ749275A (en) 2016-07-01 2023-06-30 G1 Therapeutics Inc Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
WO2018005860A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR102466192B1 (ko) 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포성 암종의 치료를 위한 조합 요법
AU2017359333B2 (en) 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
KR20240024296A (ko) 2016-12-05 2024-02-23 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
MX2019008158A (es) * 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
RU2764724C2 (ru) 2017-03-16 2022-01-19 ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. Комбинированная терапия для лечения рака молочной железы
DK3601239T3 (da) 2017-03-23 2024-09-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
EP3666774B1 (en) * 2017-08-11 2022-05-11 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor
AU2019205821C1 (en) 2018-01-08 2025-02-13 Pharmacosmos Holding A/S G1T38 superior dosage regimes
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
EP3830082B1 (en) 2018-07-27 2025-02-26 California Institute of Technology Cdk inhibitors and uses thereof
SG11202101807SA (en) 2018-08-24 2021-03-30 G1 Therapeutics Inc Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
EP3877422A4 (en) * 2018-11-09 2022-08-24 G1 Therapeutics, Inc. Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders
CA3143339A1 (en) * 2019-06-18 2020-12-24 G1 Therapeutics, Inc. Patient selection for enhancement of anti-tumor immunity in cancer patients
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
EP4652997A2 (en) 2020-05-19 2025-11-26 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
AU2021287380A1 (en) * 2020-06-11 2023-01-05 Lunella Biotech, Inc. Selective CDK4/6 inhibitor cancer therapeutics
CN116157403B (zh) * 2020-06-15 2025-04-25 海南先声再明医药股份有限公司 曲拉西利的形态及其制造方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024116069A1 (en) * 2022-11-28 2024-06-06 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
JP4555476B2 (ja) 1998-06-16 2010-09-29 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
CA2360671A1 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and therapeutic use of the same
WO2001007411A1 (en) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
AU2072201A (en) 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
SK17342002A3 (sk) 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
DK1325011T3 (da) 2000-09-29 2004-08-16 Lilly Co Eli Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
US6706718B2 (en) 2000-12-01 2004-03-16 Bristol-Myers Squibb Company 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
JP4302986B2 (ja) 2001-02-28 2009-07-29 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法
WO2002092127A1 (en) 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
AU2003221584A1 (en) 2002-05-01 2003-11-17 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AU2004240772B2 (en) 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
DK1648889T3 (da) 2003-07-11 2009-01-05 Warner Lambert Co Isethionatsalt af en selektiv CDK4-inhibitor
JP4490434B2 (ja) 2003-10-23 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 神経及び神経精神疾患の処置においてＧｌｙＴ−１阻害剤として使用するためのトリアザ−スピロピペリジン誘導体
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
EP1740184A1 (en) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
US8603763B2 (en) 2004-04-08 2013-12-10 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005117908A2 (en) 2004-05-28 2005-12-15 Gemin X Biotechnologies, Inc. Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases
CA2594425A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006077425A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
WO2007065820A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
CA2631777A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
US20070270362A1 (en) 2006-05-18 2007-11-22 The University Of Washington Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
JP2010513317A (ja) 2006-12-14 2010-04-30 パナシー ファーマシューティカルズ インコーポレーティッド サイクリン依存性キナーゼの阻害による神経保護方法
BRPI0720635A2 (pt) 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
CN101784541A (zh) 2007-06-25 2010-07-21 纽罗根公司 哌嗪基氧代烷基四氢-β-咔啉及相关类似物
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
WO2010012777A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
US8685980B2 (en) * 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
JP2012504645A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
WO2010132725A2 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
FR2957748B1 (fr) * 2010-03-16 2012-09-07 St Microelectronics Grenoble 2 Composant electronique a montage en surface
CN102299073A (zh) 2010-06-25 2011-12-28 无锡华润上华半导体有限公司 Vdmos器件及其制作方法
LT2632467T (lt) 2010-10-25 2016-09-12 G1 Therapeutics, Inc. Cdk inhibitoriai
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
SG189494A1 (en) 2010-11-02 2013-05-31 Promega Corp Coelenterazine derivatives and methods of using same
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
WO2012085244A1 (fr) 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
PH12013501940A1 (en) 2011-03-23 2015-12-04 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
CN105175396B (zh) 2011-07-27 2018-01-16 阿斯利康(瑞典)有限公司 取代的4‑甲氧基‑n3‑(嘧啶‑2‑基)苯‑1,3‑二胺化合物及其盐
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
EP2880448B1 (en) 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9241941B2 (en) 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
RU2015125307A (ru) 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия
US9464092B2 (en) * 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
CN105263496A (zh) 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
WO2015084892A1 (en) 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
WO2015101293A1 (zh) 2013-12-31 2015-07-09 山东轩竹医药科技有限公司 激酶抑制剂及其用途
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US9374037B2 (en) 2014-10-30 2016-06-21 M/A-Com Technology Solutions Holdings, Inc. Voltage-controlled oscillator with mask-selectable performance
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
NZ749275A (en) * 2016-07-01 2023-06-30 G1 Therapeutics Inc Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20240024296A (ko) * 2016-12-05 2024-02-23 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
MX2019008158A (es) * 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11395821B2 (en) * 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018148576A1 (en) * 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
RU2019142591A (ru) * 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
CN111867592A (zh) 2018-01-04 2020-10-30 G1治疗公司 用于治疗异常细胞增殖的杂环化合物
AU2019205821C1 (en) * 2018-01-08 2025-02-13 Pharmacosmos Holding A/S G1T38 superior dosage regimes
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
WO2020023502A1 (en) * 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA3143339A1 (en) * 2019-06-18 2020-12-24 G1 Therapeutics, Inc. Patient selection for enhancement of anti-tumor immunity in cancer patients
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療

Also Published As

Publication number Publication date
US10660896B2 (en) 2020-05-26
US20210213022A1 (en) 2021-07-15
US20170037051A1 (en) 2017-02-09
CN108283644B (zh) 2022-03-18
US10925878B2 (en) 2021-02-23
US20200345742A1 (en) 2020-11-05
EP2968290A4 (en) 2016-09-28
US11654148B2 (en) 2023-05-23
US20180360840A1 (en) 2018-12-20
JP7250737B2 (ja) 2023-04-03
US10966984B2 (en) 2021-04-06
US11040042B2 (en) 2021-06-22
EP2968291B1 (en) 2025-04-16
WO2014144847A2 (en) 2014-09-18
CN108283644A (zh) 2018-07-17
EP3653209A1 (en) 2020-05-20
ES2761406T3 (es) 2020-05-19
EP2968291A2 (en) 2016-01-20
US10434104B2 (en) 2019-10-08
US10076523B2 (en) 2018-09-18
CA2906166A1 (en) 2014-09-18
US20170100405A1 (en) 2017-04-13
JP6738933B6 (ja) 2020-09-09
JP7213854B2 (ja) 2023-01-27
US20140271466A1 (en) 2014-09-18
CA2906166C (en) 2023-03-14
JP2019055954A (ja) 2019-04-11
JP6767456B2 (ja) 2020-10-14
WO2014144326A1 (en) 2014-09-18
SMT201900681T1 (it) 2020-01-14
US20230364098A1 (en) 2023-11-16
PT2968290T (pt) 2019-11-27
US9464092B2 (en) 2016-10-11
JP2016513737A (ja) 2016-05-16
US20230381189A1 (en) 2023-11-30
CA2906156C (en) 2023-03-14
ME03557B (me) 2020-07-20
RS59790B1 (sr) 2020-02-28
US20190070185A1 (en) 2019-03-07
JP2016514689A (ja) 2016-05-23
CN108434149A (zh) 2018-08-24
JP2023078341A (ja) 2023-06-06
LT2968290T (lt) 2019-12-10
CA2906156A1 (en) 2014-09-18
JP2023052449A (ja) 2023-04-11
EP2968290B1 (en) 2019-09-25
US9487530B2 (en) 2016-11-08
CN105473140A (zh) 2016-04-06
HK1258477A1 (zh) 2019-11-15
CY1122434T1 (el) 2021-01-27
HK1222792A1 (zh) 2017-07-14
US10085992B2 (en) 2018-10-02
JP2020183422A (ja) 2020-11-12
US20170065597A1 (en) 2017-03-09
EP2968290A1 (en) 2016-01-20
DK2968290T3 (da) 2019-11-25
JP6337083B2 (ja) 2018-06-06
US9931345B2 (en) 2018-04-03
US20210299130A1 (en) 2021-09-30
EP2968291C0 (en) 2025-04-16
CN105407889B (zh) 2018-06-01
HRP20192168T1 (hr) 2020-02-21
JP6517401B2 (ja) 2019-05-22
EP4596051A3 (en) 2025-10-29
US20140275066A1 (en) 2014-09-18
US9527857B2 (en) 2016-12-27
JP6430483B2 (ja) 2018-11-28
CN108434149B (zh) 2021-05-28
CN105473140B (zh) 2018-04-10
JP2018150333A (ja) 2018-09-27
PL2968290T3 (pl) 2020-04-30
HUE046653T2 (hu) 2020-03-30
JP6738933B2 (ja) 2020-08-12
JP2019131609A (ja) 2019-08-08
CN105407889A (zh) 2016-03-16
EP2968291A4 (en) 2016-09-28
SI2968290T1 (sl) 2020-02-28
US20180360841A1 (en) 2018-12-20
US11717523B2 (en) 2023-08-08
US20140275067A1 (en) 2014-09-18
US20180221378A1 (en) 2018-08-09
JP2021001197A (ja) 2021-01-07
HK1223293A1 (zh) 2017-07-28
EP4596051A2 (en) 2025-08-06
WO2014144847A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
ES3032492T3 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
US20230241059A1 (en) Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors
US11090306B2 (en) Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
HK1260112B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1260112A1 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1222792B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation